Business
Endonovo Names Ira Weisberg President to Guide Global Medical Expansion
Endonovo Names Ira Weisberg President to Guide Global Medical Expansion.
About this update from Endonovo Therapeutics, Inc.
[{"type":"text","content":"\n Los Angeles, CA, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today named Ira Weisberg as President and Chief Commercial Officer of its Medical Division. “Ira will be responsible for expanding global sales and marketing operations, including: business development, acquisitions and fostering product innovation while overseeing advancement of SofPulse® and Roma® Pulsed Electro Magnetic Frequency (PEMF) medical devices distribution globally,” according to Chairman and CEO Alan Collier. Weisberg has more than four decades of experience in healthcare and pharmaceutical management, business development, finance, sales and marketing. Weisberg’s past work experience includes positions as President and CEO of Amherst Pharmaceuticals, Senior VP and Corporate Development Officer at Neurotrope Bioscience. Other executive medical administrative experience include executive positions at ALPHAVAX, INC., LIFECYCLE PHARMA, CHUGAI PHARMA USA, HAEMACURE CORPORATION and AVENTIS BEHRING. Throughout his career, Weisberg led negotiations and signed licensing deals for strategic acquisitions, distribution and development deals for multiple companies in the medical device and pharmaceutical industry. His expertise is in developing strategies to guide emerging medical companies to advance revenue and enhance company diversity, developmental pipelines and geographic reach particularly in fast-growing emerging medical device and pharmaceutical markets. Key to Strategy \"Acquisitions and distribution licensing agreements are a key part of our strategy to complement and grow our SofPulse® and Roma® PEMF portfolio globally,” according to Collier. As Senior business development director with AVENTIS BEHRING, a global leader in recombinant albumin, Weisberg negotiated out-licensing, supply, distribution and development agreements with major pharmaceutical companies in excess of $100 million and contributed to revenues for the company’s specialty product valued at $500 million while assisting the company to be valued in excess of $750 million. Collier pointed out: “Simply having Ira’s leadership and his abilities as a lead negotiator and his past performance to close large distribution deals brings a level of gravitas to the company. He understands the unique value pr...